Tagged with Merck

Czech Republic Women’s health is an increasingly significant niche for pharma companies operating in the Czech Republic, with large areas of unmet need and opportunities for growth.   We have great expectations [because] fertility as a therapeutic area is the one in which I identify the largest potential for the future Rene…

Pharma Merck Czech Republic’s MD reveals his plan to double Merck operations within the next five years and talks about the impact of the recent acquisition of Sigma Aldrich on the Czech Republic. You’ve assumed position as Managing Director Merck Czech Republic just over one year ago; what was the strategy…

Pharma As President of Biopharma Activities for Merck in France, Pierre-Henry Longeray reveals how France is the third ranked affiliate after the US and Germany for the Group; how the French culture of innovation is one of the main drivers of the business; and how Merck is shifting from a pharmaceutical…

Pharma Automation and consolidation have affected pharmaceutical companies worldwide, and Puerto Rico is no exception. The island has benefited from the trend towards lower volume, higher value products which often use the smaller plants Puerto Rico offers. Some companies, like Merck, are transforming their sites from pure manufacturing to commercialization. These trends point to…

Pharma The Managing Director of MSD Egypt highlights MSD’s unique incentives to further collaborate with the Egyptian medical community and explains how market peculiarities shape product launches in developing countries like Egypt. As newly appointed Managing Director for MSD Egypt, could you please outline your objectives and ambitions in the Egyptian…

manufacturing Pepe Rodríguez-Pérez, president of Business Excellence Consulting, tell us how he helps companies in Spain and Latin America enter the US market through Puerto Rico. He explains why he is cautious about Puerto Rico’s manufacturing growth potential. What are the factors which have led to the decline of the industry over the…

Merck Merck’s managing director for South Africa and general manager for Southeast Africa reveals why the company takes a long-term perspective when investing in African countries, helping to shape healthcare systems, working on CSR initiatives and public/private partnerships by partnering with governments, how the way of doing business on the continent…

MSD MSD Turkey has benefited in recent years from the ability to engage in local business development initiatives, and managing director Hatice Demiray has prioritized initiatives such as reducing internal bureaucracy and incentivizing CRM use to improve operational efficiencies. You took over last year as managing director of MSD Turkey, after…

Merck The country manager of a leading company for innovative and top-quality high-tech products in healthcare, life science and performance materials describes the initiatives she has been putting in place to optimise and streamline the business during a period of belt tightening and increased regulatory forces. Of particular note are the innovative…

Merck Andrew Wirths arrived to Puerto Rico in 2013 to run Merck’s manufacturing operations on the island. He discusses how dynamic changes within the industry is impacting their competitive nature and recent investments that Merck is making in Puerto Rico’s facilities, which represent a key part of the company’s commercialization process.…

Array Deborah Brown, President of EMD Serono Canada, talks about Canada’s emerging market mentality, despite being a developed country, and how this lack of innovation and risk-taking could ultimately break Canada’s healthcare system if not addressed immediately. You have been responsible for a number of EMD Serono product launches in Canada;…

UAE Paolo Carli, Head of Middle East, KSA & Egypt for Merck Serono, speaks about the regions most pressing health issues—hypertension and diabetes— and how he thinks that collaboration of the industry with the government and educational institutes will help overcome this problem before it’s too late.   Our approach to…